Most neurodegenerative disorders are associated with aggregated protein deposits. In the
case of Alzheimer disease (AD), extracellular amyloid-β (Aβ) aggregates and intracellular …

Cerebrospinal fluid analyses and neuroimaging can identify the underlying pathophysiology
at the earliest stage of some neurodegenerative disorders, but do not have the scalability …

The effects of acute sleep deprivation on β-amyloid (Aβ) clearance in the human brain have
not been documented. Here we used PET and 18F-florbetaben to measure brain Aβ burden …

Objective To determine the in vivo cortical spreading pattern of tau and amyloid and to
establish positron emission tomography (PET) image‐based tau staging in the Alzheimer …

Background Evaluation of brain β‐amyloid by positron emission tomography (PET) imaging
can assist in the diagnosis of Alzheimer disease (AD) and other dementias. Methods Open …

Alzheimer's disease (AD) is a devastating and progressive neurodegenerative disease for
which there is no cure. Mild cognitive impairment (MCI) is considered a prodromal stage of …

Many clinical applications based on deep learning and pertaining to radiology have been
proposed and studied in radiology for classification, risk assessment, segmentation tasks …

Alzheimer's disease (AD) is a neurodegenerative disorder associated with a severe loss in
thinking, learning, and memory functions of the brain. To date, no specific treatment has …

Two centuries ago in 1817, James Parkinson provided the first medical description of
Parkinson's disease, later refined by Jean-Martin Charcot in the mid-to-late 19th century to …

Objective: To model the temporal trajectory of β-amyloid accumulation using serial amyloid
PET imaging. Methods: Participants, aged 70–92 years, were enrolled in either the Mayo …